Forget the fridge, wait for vaccine in sugarbox

A low-cost child vaccine that can be transported and stored in the most remote villages without need for refrigeration will be out in a coup...

A low-cost child vaccine that can be transported and stored in the most remote villages without need for refrigeration will be out in a couple of years.

Indian and British biotech scientists who started work in 2001 on a vaccine that can be stored without refrigeration, announced on Tuesday that their breakthrough will cut the cost of vaccinating a single child from 30 to roughly 10.

The two firms 8212; UK8217;s Cambridge Biostability Ltd CBL and India8217;s Panacea Biotec 8212; said they are now only waiting to transport their 150 scientists who worked on the project into a new research and development R038;D facility near Chandigarh, where human trials will begin early next year.

8216;8216;Most vaccines work only if stored in a temperature ranging from 2-8 degrees. We discovered that when tweaked by Panacea, CBL8217;s 8216;stable liquid8217; technology keeps vaccines potent throughout their life cycle, entirely without cold storage. This will drastically cut vaccination costs and make vaccines far more accessible to the poor,8217;8217; said Rajesh Jain, joint-MD, Panacea Biotec.

nbsp;	Cold-chain comfort

		nbsp;	8226; New technology keeps vaccines potent in sugar crystals 8226; DCGI has given clearance for human trials, to take two years 8226; WHO says approach promising, provided costs stay competitive 8226; If successful, can cut vaccine development costs by a third	nbsp;

A fresh grant of 1.7 mn from Britain8217;s Department for Industrial Development DFID will assist joint human trials into Panacea8217;s five-in-one vaccine cocktail. The vaccine will prevent measles, rubella, tetanus, whooping cough and diptheria: five preventive illnesses that two million children in developing countries die from every year.

8216;8216;Our vaccine will help save 200 mn that goes into creating cold storage facilities and another 100 mn in vaccines that go waste every year due to improper storage facilites,8217;8217; said Jain.

Roughly one-third of the money spent on developing a new vaccine goes into packaging and delivery, which need to be tailored to suit cold-storage requirements. Only half to one-third of the money goes directly into vaccine development.

Story continues below this ad

CBL8217;s arrangement coats molecules in protective sugar crystals that dissolve only in the water found in human bodies, and Panacea has adopted the system to human vaccines.

It will begin marketing the invention through international aid agencies, governments and health associations once trials end.

The company, which has clearance from the Drug Controller General of India DCGI for human trials, will approach it for clearance once human tests are through.

DCGI Ashwini Kumar told The Indian Express: 8216;8216;The technology is breakthrough, though success depends on resources and thoroughness of clinical trials, that will go into eventual proof of concept.8217;8217;

Story continues below this ad

The World Health Organization WHO told the New Scientist that the two firms8217; approach is 8216;8216;promising8217;8217;, provided the costs of clinical trials remain competitive.

Jain says the clinical trials will be over in a couple of years as the application 8212; and not the vaccines 8212; is the breakthrough.

Panacea, which started as a medicine store in 1927, had revenues of 70 million Rs 285 crore last year.

It spends 4 per cent of its turnover on R038;D.